loadpatents
name:-0.37878799438477
name:-0.026053905487061
name:-0.032809019088745
Acerta Pharma B.V. Patent Filings

Acerta Pharma B.V.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Acerta Pharma B.V..The latest application filed is for "crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1- -yl)-n-(pyridin-2-yl)benzamide".

Company Profile
28.29.47
  • Acerta Pharma B.V. - Oss NL
  • ACERTA PHARMA B.V. - AB Oss NL
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1- -yl)-n-(pyridin-2-yl)benzamide
App 20220177476 - Blatter; Frtiz ;   et al.
2022-06-09
PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN- -1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE
App 20220127270 - BETHEL; Paul Allen ;   et al.
2022-04-28
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
App 20220088013 - Hamdy; Ahmed ;   et al.
2022-03-24
BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
App 20210346382 - Hamdy; Ahmed ;   et al.
2021-11-11
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
Grant 11,166,951 - Hamdy , et al. November 9, 2
2021-11-09
Therapeutic combinations of a MEK inhibitor and a BTK inhibitor
Grant 11,154,554 - Rothbaum , et al. October 26, 2
2021-10-26
Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
App 20210322408 - Lannutti; Brian ;   et al.
2021-10-21
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
Grant 11,110,088 - Barf , et al. September 7, 2
2021-09-07
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Grant 11,090,302 - Hamdy , et al. August 17, 2
2021-08-17
Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-- yl)-N-(pyridin-2-yl)benzamide maleate
Grant 11,059,829 - Blatter , et al. July 13, 2
2021-07-13
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
Grant 10,858,364 - Podoll , et al. December 8, 2
2020-12-08
Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase
App 20200330461 - Barf; Tjeerd ;   et al.
2020-10-22
Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1- -yl)-N-(pyridin-2-yl)benzamide malea
App 20200255437 - Kind Code
2020-08-13
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
Grant 10,736,893 - Barf , et al. A
2020-08-11
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-- yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma
Grant 10,640,509 - Blatter , et al.
2020-05-05
Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
App 20200069668 - Lannutti; Brian ;   et al.
2020-03-05
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
App 20200069796 - Hamdy; Ahmed ;   et al.
2020-03-05
BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
App 20190381044 - Hamdy; Ahmed ;   et al.
2019-12-19
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
App 20190374539 - Rothbaum; Wayne ;   et al.
2019-12-12
Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
App 20190376971 - Barf; Tjeerd ;   et al.
2019-12-12
Therapeutic Combinations of an Antifolate and a BTK Inhibitor
App 20190374543 - Kaptein; Allard ;   et al.
2019-12-12
Therapeutic Combination of a PI3K Inhibitor and a BTK Inhibitor
App 20190358235 - HAMDY; Ahmed ;   et al.
2019-11-28
Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase
App 20190345164 - Podoll; Terry ;   et al.
2019-11-14
Solid Forms and Formulations of Imidazopyrazine Compound
App 20190337949 - Blatter; Fritz ;   et al.
2019-11-07
Methods And Compositions For Use Of Therapeutic T Cells In Combination With Kinase Inhibitors
App 20190328786 - PORTS; Michael ;   et al.
2019-10-31
Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesi
App 20190314369 - Lannutti; Brian ;   et al.
2019-10-17
Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor
App 20190290644 - Hamdy; Ahmed ;   et al.
2019-09-26
Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase
App 20190231775 - Izumi; Raquel ;   et al.
2019-08-01
Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
App 20190209591 - Lannutti; Brian ;   et al.
2019-07-11
Therapeutic combination of PI3K inhibitor and a BTK inhibitor
Grant 10,328,080 - Hamdy , et al.
2019-06-25
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Grant 10,272,083 - Hamdy , et al.
2019-04-30
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
App 20190022092 - Rothbaum; Wayne ;   et al.
2019-01-24
Therapeutic Combinations of an Antifolate and a BTK Inhibitor
App 20190008869 - Kaptein; Allard ;   et al.
2019-01-10
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
App 20190008859 - Rothbaum; Wayne ;   et al.
2019-01-10
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Grant 10,167,291 - Blatter , et al. J
2019-01-01
BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
App 20180369244 - Hamdy; Ahmed ;   et al.
2018-12-27
Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase
App 20180318297 - Barf; Tjeerd ;   et al.
2018-11-08
Methods of Using BTK Inhibitors to Treat Dermatoses
App 20180318304 - Krejsa; Cecile M.
2018-11-08
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor
App 20180250400 - Hamdy; Ahmed ;   et al.
2018-09-06
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
App 20180250298 - Hamdy; Ahmed ;   et al.
2018-09-06
Solid Forms and Formulations of Imidazopyrazine Compound
App 20180208596 - Blatter; Fritz ;   et al.
2018-07-26
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor
App 20180207154 - Hamdy; Ahmed ;   et al.
2018-07-26
Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase
App 20180193337 - Izumi; Raquel ;   et al.
2018-07-12
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
Grant 9,949,971 - Hamdy , et al. April 24, 2
2018-04-24
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
Grant 9,937,171 - Izumi , et al. April 10, 2
2018-04-10
Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-- yl)-N-(pyridin-2-yl)benzamide
Grant 9,796,721 - Blatter , et al. October 24, 2
2017-10-24
Therapeutic Combination of PI3K Inhibitor and a BTK Inhibitor
App 20170266191 - Hamdy; Ahmed ;   et al.
2017-09-21
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
App 20170239351 - Hamdy; Ahmed ;   et al.
2017-08-24
BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
App 20170231995 - Hamdy; Ahmed ;   et al.
2017-08-17
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
App 20170231986 - Hamdy; Ahmed ;   et al.
2017-08-17
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
App 20170224819 - Hamdy; Ahmed ;   et al.
2017-08-10
Methods of Using BTK Inhibitors to Treat Dermatoses
App 20170224688 - Krejsa; Cecile M.
2017-08-10
Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate
App 20170143712 - Lannutti; Brian ;   et al.
2017-05-25
Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor
App 20170136014 - Hamdy; Ahmed ;   et al.
2017-05-18
Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor
App 20170095471 - Ahmed; Hamdy ;   et al.
2017-04-06
Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
App 20170071962 - Lannutti; Brian ;   et al.
2017-03-16
Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
App 20170035881 - Lannutti; Brian ;   et al.
2017-02-09
Methods Of Blocking The Cxcr-4/sdf-1 Signaling Pathway With Inhibitors Of Bruton's Tyrosine Kinase
App 20170035756 - IZUMI; Raquel ;   et al.
2017-02-09
Solid Forms and Formulations of Imidazopyrazine Compound
App 20170029428 - Blatter; Fritz ;   et al.
2017-02-02
Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
Grant 9,522,917 - Izumi , et al. December 20, 2
2016-12-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed